> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tecentriq Study in Urothelial Cancer Misses Endpoint
- URL: https://www.fdaweb.com/tecentriq-study-in-urothelial-cancer-misses-endpoint/
- Published: 2020-01-24T12:00:00.000Z
- Updated: 2026-09-14T15:59:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145925

A Genentech Phase 3 study (IMvigor010) evaluating Tecentriq (atezolizumab) in people with muscle-invasive bladder (urothelial) cancer did not meet its primary endpoint of disease-free survival. The company says more treatment options are needed after surgery because about half of patients will see disease recurrence within two years after surgery, it says.

Tecentriq is a monoclonal antibody that is designed to bind with the protein PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, which may enable T cell re-activation. The drug is currently approved for treating urothelial carcinoma. The company says it is also being studied in genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.